Tricyclic pharmacophore-based molecules as novel integrin αvβ3 antagonists. Part IV: Preliminary control of αvβ3 selectivity by meta-oriented substitution

Dai Kubota, Minoru Ishikawa, Midori Ishikawa, Naokazu Yahata, Shoichi Murakami, Kazuyuki Fujishima, Masafumi Kitakaze, Keiichi Ajito

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)


To establish the in vivo efficacy of αvβ3IIbβ3 dual antagonists possessing a tricyclic pharmacophore, a corresponding αvβ3-selective antagonist was required as a control. We initially took two synthetic approaches to obtain αvβ3-selective antagonists based on the RGD recognition pattern or on modification of the dihedral angle between the central benzene ring and the adjacent heterocycle, but both proved unsuccessful. However, synthesis of novel antagonists with meta-substitution of the central benzene ring generated weak selectivity for αvβ3 over αIIbβ3 for the first time in the family of compounds with the tricyclic pharmacophore. Optimization of meta-oriented antagonists furnished an αvβ3-selective antagonist exhibiting inhibitory activity not only in a receptor-binding assay, but also in a cell adhesion assay.

Original languageEnglish
Pages (from-to)4158-4181
Number of pages24
JournalBioorganic and Medicinal Chemistry
Issue number12
Publication statusPublished - 2006 Jun 15
Externally publishedYes


  • Acute ischemic disease
  • Integrin αβ antagonist
  • Integrin αβ-selective antagonist
  • meta-Oriented substitution

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Fingerprint Dive into the research topics of 'Tricyclic pharmacophore-based molecules as novel integrin α<sub>v</sub>β<sub>3</sub> antagonists. Part IV: Preliminary control of α<sub>v</sub>β<sub>3</sub> selectivity by meta-oriented substitution'. Together they form a unique fingerprint.

Cite this